Condition (MeSH)
Mesonephroma
ClinicalTrials.gov lists 49 trials for Mesonephroma or a narrower condition beneath it. Children's Oncology Group has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Mesonephroma trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2011 | 1 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mesonephroma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 1/2 | 2 |
| Phase 2 | 16 |
| Phase 2/3 | 2 |
| Phase 3 | 12 |
| Not applicable | 4 |
| Observational | 3 |
How many Mesonephroma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 7 |
| Active, not recruiting | 3 |
| Completed | 35 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mesonephroma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 5 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Medical Research Council | 2 |
| National Cancer Institute (NCI) | 2 |
| Eastern Cooperative Oncology Group | 1 |
Which drugs are being tested for Mesonephroma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 10 |
| Bleomycin | 8 |
| PEGFILGRASTIM | 3 |
| G-CSF | 2 |
| Cytoxan | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cisplatin 1 | 13 |
| Etoposid | 11 |
| Ifosfamid | 10 |
| Filgrastime (G-CSF) | 8 |
| or carboplatin | 7 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mesonephroma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutropenia | 43 | 1 |
| Fever | 17 | 2 |
| Vomiting | 16 | 3 |
| Febrile neutropenia | 14 | 1 |
| Nausea | 14 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Mesonephroma? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. | Obstetrics and gynecology | 1971 | No |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.